The relative expression of the top three differentially expressed genes (CDKN1A, MAP1B and EGLN2), identified using RNAseq analysis, has confirmed the dysregulation of their mRNA levels in the replication group of RR and SP MS patients’ PBMCs by qPCR (Figure 6). Here, EGLN2 is linked to myeloid sarcoma.